Penumbra Q1 2025 revenue rises 16.3% to $324.1 million; net income $39.2 million
Penumbra reported first quarter 2025 revenue of $324.1 million, up 16.3% from a year earlier, and net income of $39.2 million, compared with $11.0 million in the first quarter of 2024. The company reiterated its full-year 2025 revenue guidance of $1,340 million to $1,360 million and raised its U.S. Thrombectomy growth outlook to 20% to 21%.
Key points
- Revenue $324.1 million, up 16.3% (16.9% in constant currency) from $278.7 million in Q1 2024
- Net income $39.2 million, or $1.00 diluted EPS, versus $11.0 million, or $0.28 diluted EPS, a year earlier
- Full-year 2025 revenue guidance of $1,340 million to $1,360 million reiterated
- U.S. Thrombectomy growth guidance raised to 20% to 21% from 19% to 20%
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 23, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.